CN1073996C - 二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途 - Google Patents

二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途 Download PDF

Info

Publication number
CN1073996C
CN1073996C CN95109527A CN95109527A CN1073996C CN 1073996 C CN1073996 C CN 1073996C CN 95109527 A CN95109527 A CN 95109527A CN 95109527 A CN95109527 A CN 95109527A CN 1073996 C CN1073996 C CN 1073996C
Authority
CN
China
Prior art keywords
methyl
acetyl
dihydro
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95109527A
Other languages
English (en)
Chinese (zh)
Other versions
CN1128264A (zh
Inventor
B·A·安德逊
M·M·汉森
J·T·文森齐
D·L·瓦里
小·M·J·兹米祖斯基
E·G·格罗卢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/412,242 external-priority patent/US6329364B1/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1128264A publication Critical patent/CN1128264A/zh
Application granted granted Critical
Publication of CN1073996C publication Critical patent/CN1073996C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN95109527A 1994-08-31 1995-08-30 二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途 Expired - Fee Related CN1073996C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US412,242 1989-09-25
US29864594A 1994-08-31 1994-08-31
US298645 1994-08-31
US298,645 1994-08-31
US412242 1995-03-28
US08/412,242 US6329364B1 (en) 1994-08-31 1995-03-28 Crystalline form of dihydro-2,3-benzodiazepine derivative

Publications (2)

Publication Number Publication Date
CN1128264A CN1128264A (zh) 1996-08-07
CN1073996C true CN1073996C (zh) 2001-10-31

Family

ID=26970796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95109527A Expired - Fee Related CN1073996C (zh) 1994-08-31 1995-08-30 二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途

Country Status (19)

Country Link
EP (1) EP0699678B1 (fr)
JP (1) JP3449835B2 (fr)
CN (1) CN1073996C (fr)
AT (1) ATE262531T1 (fr)
AU (1) AU695424B2 (fr)
BR (1) BR9503843A (fr)
CA (1) CA2157248C (fr)
CZ (1) CZ288679B6 (fr)
DE (1) DE69532739T2 (fr)
DK (1) DK0699678T3 (fr)
ES (1) ES2214491T3 (fr)
FI (1) FI112489B (fr)
HU (1) HU223843B1 (fr)
IL (1) IL115102A (fr)
NO (1) NO309192B1 (fr)
NZ (1) NZ272898A (fr)
PL (1) PL181086B1 (fr)
PT (1) PT699678E (fr)
TR (1) TR199501070A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
ATE255112T1 (de) * 1997-08-12 2003-12-15 Egyt Gyogyszervegyeszeti Gyar 1-3 dioxolo/4.5-h//2,3-benzodiazepin derivate als ampa/kainate-rezeptor-hemmer
UA67749C2 (uk) * 1997-08-12 2004-07-15 Егіш Дьйодьсердьяр Рт. Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492485A1 (fr) * 1990-12-21 1992-07-01 Gyogyszerkutato Intezet Dérivés de N-acyl-2,3-benzodiazépine, compositions pharmaceutiques les contenant et procédé pour leur préparation
WO1995001357A1 (fr) * 1993-07-02 1995-01-12 Gyógyszerkutató Intézet Kft. 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h2-,3 -benzodiazepine optiquement actif et procede de preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492485A1 (fr) * 1990-12-21 1992-07-01 Gyogyszerkutato Intezet Dérivés de N-acyl-2,3-benzodiazépine, compositions pharmaceutiques les contenant et procédé pour leur préparation
WO1995001357A1 (fr) * 1993-07-02 1995-01-12 Gyógyszerkutató Intézet Kft. 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h2-,3 -benzodiazepine optiquement actif et procede de preparation

Also Published As

Publication number Publication date
HU9502549D0 (en) 1995-10-30
DK0699678T3 (da) 2004-06-28
NZ272898A (en) 1996-12-20
FI954066A0 (fi) 1995-08-30
NO953394L (no) 1996-03-01
CZ288679B6 (cs) 2001-08-15
NO953394D0 (no) 1995-08-30
AU695424B2 (en) 1998-08-13
HU223843B1 (hu) 2005-02-28
DE69532739T2 (de) 2005-03-17
EP0699678A1 (fr) 1996-03-06
CN1128264A (zh) 1996-08-07
HUT72675A (en) 1996-05-28
ATE262531T1 (de) 2004-04-15
TR199501070A2 (tr) 1996-06-21
PT699678E (pt) 2004-07-30
NO309192B1 (no) 2000-12-27
HK1013820A1 (en) 1999-09-10
ES2214491T3 (es) 2004-09-16
PL181086B1 (pl) 2001-05-31
EP0699678B1 (fr) 2004-03-24
BR9503843A (pt) 1996-09-10
FI954066L (fi) 1996-03-01
FI112489B (fi) 2003-12-15
JPH0881469A (ja) 1996-03-26
PL310228A1 (en) 1996-03-04
AU3035795A (en) 1996-03-14
DE69532739D1 (de) 2004-04-29
IL115102A (en) 1998-12-27
CZ222195A3 (en) 1996-03-13
CA2157248C (fr) 2000-02-22
JP3449835B2 (ja) 2003-09-22
IL115102A0 (en) 1995-12-08
CA2157248A1 (fr) 1996-03-01

Similar Documents

Publication Publication Date Title
KR101380190B1 (ko) 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
CN1040440C (zh) 去氢环黄皮酰胺衍生物的制备方法
CN1073996C (zh) 二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途
US6288057B1 (en) Physical form of dihydro-2,3-benzodiazepine derivative
CN1073995C (zh) 二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途
CN1086705C (zh) 制备二氢－2,3－苯并二氮杂䓬衍生物立体有择方法和中间体
US5795886A (en) Dihydro-2,3-benzodiazepine derivatives
US5496847A (en) Aminomethyl-benzodioxane and benzopyran serotonergic agents
KR20100057035A (ko) (ｓ)-2-((4-벤조푸라닐)카르보닐아미노메틸)-1-((4-(2-메틸-5-(4-플루오로페닐))티아졸릴)카르보닐)피페리딘의 다형체 형태
RU2146677C1 (ru) Физическая форма (r)-7-ацетил-5-(4-аминофенил)-8,9-дигидро-8-метил-7н-1,3- диоксоло[4,5-h]-[2,3]-бензодиазепина, способ ее получения и фармацевтическая композиция
HK1013820B (en) Crystalline form of dihydro-2,3-benzodiazepine derivative
HK1013819B (en) Physical form of dihidro-2,3-benzodiazepine derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20011031

Termination date: 20100830